Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Additional provision for US RMBS investigations

26 Jan 2017 07:00

RNS Number : 1779V
Royal Bank of Scotland Group PLC
26 January 2017
 

The Royal Bank of Scotland Group plc

Additional provision for US RMBS investigations and litigation

 

26 January 2017

 

 

The Royal Bank of Scotland Group plc (together with its subsidiaries, "RBS") will announce its Full Year 2016 results on 24 February 2017. Subject to any increase being required by intervening developments, the Q4 2016 results will reflect the taking of a further £3.1bn ($3.8bn) provision in relation to various investigations and litigation matters relating to RBS's issuance and underwriting of US residential mortgage-backed securities ("RMBS"). This takes the total aggregate of such provisions to £6.7bn ($8.3bn) as at 31 December 2016. This further provision would have reduced RBS's Tangible Net Asset Value ("TNAV") per share at 30 September 2016 by 27p to 311p and RBS's Q3 2016 CET1 capital ratio by 135bps to 13.6%. This provision does not directly impact the distributable reserves of The Royal Bank of Scotland Group plc.

 

RBS continues to cooperate with the US Department of Justice ("DOJ") in its civil and criminal investigations of RMBS matters, and RBS considers it appropriate to take this provision now in relation to those investigations as well as other RMBS litigation matters. The duration and outcome of these investigations and other RMBS litigation matters remain uncertain, including in respect of whether settlements for all or any of such matters may be reached.

 

RBS emphasises that further substantial additional provisions and costs may be recognised and, depending on the final outcome, other adverse consequences may occur (see RBS's existing market disclosures). The existing disclosures also provide further details of the US RMBS-related investigations by the DOJ and other agencies and bodies, including several state attorneys general, and various litigation matters.

 

Ross McEwan, RBS's Chief Executive Officer, said:

 

"Putting our legacy litigation issues behind us, including those relating to RMBS, remains a key part of our strategy. It is our priority to seek the best outcome for our shareholders, customers and employees."

 

Ross McEwan (Chief Executive Officer) and Ewen Stevenson (Chief Financial Officer) will host a conference call for investors and analysts at 8.00am UK time today. A replay of the call will be made available shortly afterwards. Only items relating to the above announcement will be discussed on the call; there will be no references and discussion relating to other matters and the Full Year 2016 results. Dial-in details for the call can be found below.

 

Dial-in details:

UK: 0800 694 8082

International: +44 (0) 1452 568 172

US: +1 866 966 8024

Conference ID: 60246489

 

Replay details:

UK FreeCall: 0800 953 1533

Std International: +44 (0)1452 550 000

USA FreeCall: +1 (866) 247 4222

Conference ID: 60246489

 

 

For further information, please contact:

 

Investor Relations

Alexander Holcroft

Head of Equity Investor Relations

+44 (0) 20 7672 1758

 

Matthew Richardson

Head of Fixed Income Investor Relations

+44 (0) 20 7678 1800

 

RBS Media Relations

+44 (0) 131 523 4205

 

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to RBS and its subsidiaries' regulatory capital position, risk-weighted assets, impairment losses and credit exposures under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements concern or may affect future matters, such as RBS's future economic results, business and capital plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, fiscal and regulatory developments, competitive conditions, technological developments, exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBS's actual results are discussed in RBS's UK Annual Report and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, RBS's Reports on Form 6-K and most recent Annual Report on Form 20-F. The forward-looking statements contained in this announcement speak only as of the date of this announcement and RBS does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

Legal Entity Identifier: 2138005O9XJIJN4JPN90

 

ENDS

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQQLBLDFFZBBX
Date   Source Headline
17th Mar 20205:24 pmRNSDirectorate Change
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
17th Mar 20208:30 amRNSMorgan Stanley European Financials Conference
16th Mar 20205:14 pmRNSNatWest Markets N.V. 2019 ARA
10th Mar 20204:51 pmRNSDirector/PDMR Shareholding
2nd Mar 20202:34 pmRNSDirector/PDMR Shareholding
28th Feb 20204:29 pmRNSCorrection of Dividend Declaration
28th Feb 20201:58 pmRNSTotal Voting Rights and Capital
28th Feb 20207:00 amRNSFiling of Annual Report on Form 20-F with US SEC
27th Feb 20209:55 amRNSBlock Listing Cancellation
24th Feb 202012:40 pmRNSDividend Declaration
20th Feb 20204:10 pmRNSHolding(s) in Company
14th Feb 20203:58 pmRNSRBSG ENTM Publication of Suppl.Prospcts
14th Feb 20207:01 amRNSAnnual Financial Report
14th Feb 20207:00 amRNSFinal Results
31st Jan 20202:12 pmRNSTotal Voting Rights and Capital
30th Jan 20203:57 pmRNSDirector/PDMR Shareholding
16th Jan 20202:08 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Jan 20201:58 pmRNSForm 8.3 - Accesso Technology Group plc
31st Dec 20191:10 pmRNSDirector/PDMR Shareholding
31st Dec 201911:20 amRNSTotal Voting Rights and Capital
30th Dec 20193:02 pmRNSForm 8.3 - Accesso Technology Group plc
20th Dec 20197:00 amRNSPublication of Suppl.Prospcts replacement
19th Dec 20195:40 pmRNSPublication of Suppl.Prospcts
19th Dec 20197:00 amRNSNatWest Markets Change in Executive Directors
16th Dec 20195:47 pmRNS2019 Bank of England stress test results
4th Dec 201912:34 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Dec 20195:34 pmRNSPublication of Suppl.Prospcts
29th Nov 20192:20 pmRNSDirector/PDMR Shareholding
29th Nov 20191:28 pmRNSAnnouncement of NatWest Markets N.V. Transfer
29th Nov 201912:01 pmRNSTotal Voting Rights and Capital
27th Nov 201911:56 amRNSDividend Declaration
21st Nov 20196:26 pmRNSPublication of a Prospectus
21st Nov 201910:45 amRNSReduction in Pillar 2A capital requirements
14th Nov 201911:23 amRNSPublication of Final Terms
13th Nov 20193:00 pmRNSForm 8.3 - Accesso Technology Group plc
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
1st Nov 20194:12 pmRNSDirector/PDMR Shareholding
31st Oct 20193:30 pmRNSDirector/PDMR Shareholding
31st Oct 20192:08 pmRNSTotal Voting Rights and Capital
30th Oct 20199:38 amRNSRBSG pricing of US$750mn of Subordinated Notes
25th Oct 20195:22 pmRNSPublication of Suppl.Prospcts
24th Oct 20197:00 amRNSQ3 Interim Management Statement
16th Oct 20192:54 pmRNSForm 8.3 - Accesso Technology Group plc
8th Oct 201911:35 amRNSBlock Listing Six Monthly Return
3rd Oct 20191:08 pmRNSPublication of Final Terms
1st Oct 20195:29 pmRNSDirector/PDMR Shareholding
30th Sep 20193:28 pmRNSTotal Voting Rights
24th Sep 20198:30 amRNSBank of America Merrill Lynch Annual Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.